Analysts’ Recent Ratings Updates for Iambic Therapeutics (IAM)

Iambic Therapeutics (NASDAQ: IAM) recently received a number of ratings updates from brokerages and research firms:

• 11/10/2026 – Iambic Therapeutics is now covered by Jefferies Financial Group. They set a “buy” rating and a $35.00 price target on the stock.
• 11/9/2026 – Iambic Therapeutics is now covered by JPMorgan Chase & Co.. They set an “overweight” rating and a $22.00 price target on the stock.
• 11/9/2026 – Iambic Therapeutics is now covered by Citigroup. They set a “buy” rating and a $22.00 price target on the stock.
• 11/9/2026 – Iambic Therapeutics is now covered by Bank of America. They set a “buy” rating and a $30.00 price target on the stock.
• 11/7/2026 – Iambic Therapeutics was upgraded by Wall Street Zen to “hold”.

Iambic Therapeutics Stock Performance

Shares of NASDAQ:IAM opened at $13.82 on Tuesday. Iambic Therapeutics, Inc. has a 52-week low of $9.60 and a 52-week high of $25.00.

Insiders Place Their Bets

In other news, Director Evan Lockwood Rachlin acquired 718,750 shares of the stock in a transaction that occurred on Friday, October 16th. The shares were bought at an average cost of $16.00 per share, for a total transaction of $11,500,000.00. Following the acquisition, the director owned 2,588,248 shares in the company, valued at approximately $41,411,968. This represents a 38.45% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 22.90% of the company’s stock.